Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer ; volume:8 ; number:1 ; day:2 ; month:3 ; year:2018 ; pages:1-12 ; date:12.2018
Scientific reports ; 8, Heft 1 (2.3.2018), 1-12, 12.2018
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Mansour, W. Y.
- Beteiligte Personen und Organisationen
-
Tennstedt, P.
Volquardsen, J.
Oing, C.
Kluth, M.
Hube-Magg, C.
Borgmann, K.
Simon, R.
Petersen, C.
Dikomey, E.
Rothkamm, K.
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-22289-7
- URN
-
urn:nbn:de:1111-201804251534
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mansour, W. Y.
- Tennstedt, P.
- Volquardsen, J.
- Oing, C.
- Kluth, M.
- Hube-Magg, C.
- Borgmann, K.
- Simon, R.
- Petersen, C.
- Dikomey, E.
- Rothkamm, K.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
PHF6 promotes non‐homologous end joining and G2 checkpoint recovery
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
The role of homologous recombination repair in the processing of G2-chromosomal breaks and maintenance of G2-checkpoint
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
PHF6 promotes non‐homologous end joining and G2 checkpoint recovery
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
The role of homologous recombination repair in the processing of G2-chromosomal breaks and maintenance of G2-checkpoint
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Apigenin impedes cell cycle progression at G2 phase in prostate cancer cells
PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
PHF6 promotes non‐homologous end joining and G2 checkpoint recovery
Homologous Recombination Deficiency Unrelated to Platinum and PARP Inhibitor Response in Cell Line Libraries
The role of homologous recombination repair in the processing of G2-chromosomal breaks and maintenance of G2-checkpoint
Homologous repair deficiencies and current insights in clinical evaluation of PARP inhibitors in prostate cancer
The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors